期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

膜结合型前列腺素E合成酶1及其表达与肿瘤相关性的研究进展 被引量：2

下载PDF
导出
摘要 膜结合型前列腺素E合成酶1(membrane-associated prostaglandin E synthase-1,mPGES-1)是前列腺素(prostaglandin,PG)E2生物合成过程中重要的终端限速酶,与环氧合酶2(cyclooxygenase-2,COX-2)功能性偶联参与机体多种生理及病理过程。近年来研究发现,mPGES-1在多种肿瘤组织中过度表达,与肿瘤的发生、发展密切相关。抑制mPGES-1的活性能有效降低PGE2的产生,同时能避免非甾体类抗炎药(non-steroidal anti-inflammatory drug,NSAID)及COX-2特异性抑制剂引起的心血管方面的不良反应,是一个比COX-2更理想、更安全的防治肿瘤的药物开发新靶点。本文就mPGES-1的分子生物学特征、与肿瘤发生和发展的相关性及其抑制剂的研究进展作一综述。
作者 欧阳林旗 刘世坤
机构地区 中南大学药学院 中南大学湘雅三医院药剂科
出处 《肿瘤》 CAS CSCD 北大核心 2009年第12期1180-1183,共4页 Tumor
关键词 肿瘤 前列腺素E类 基因表达 膜结合型前列腺素E合成酶1 膜结合型前列腺素E合成酶1抑制剂
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献32

  • 1CASTELLONE M D, TERAMOTO H, WILLIAMS B O, et al. Prostaglandin E2 promotes colon cancer cell growth through a Gsaxin-beta-catenin signaling axis[J]. Science, 2005, 310(5753) : 1504-1510.
  • 2陈刚,段惠君.不同剂量塞来昔布对人肺癌裸鼠移植瘤的治疗作用及机制研究[J].肿瘤,2008,28(10):837-841. 被引量：8
  • 3MCGETTIGAN P, HENRY D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2 [J]. JAMA, 2006, 296( 13): 1633-1644.
  • 4SAMUELSSON B, MORGENSTERN R, JAKOBSSON P J. Membrane prostaglandin E synthase-1: a novel therapeutic target [ J]. Pharmacol Rev, 2007, 59 ( 3 ) : 207-224.
  • 5MEHROTRA S, MORIMIYA A, AGARWAL B, et al. Microsomal prostaglandin E2 synthase-1 in breast cancer: A potential target for therapy[J]. J Pathol, 2006, 208(3): 356-363.
  • 6WANG M, LEE E, SONG W, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin Ⅱ- induced abdominal aortic aneurysm formation [J]. Circulation, 2008, 117(10): 1302-1309.
  • 7MURAKAMI M, NAKASHIMA K, KAMEI D, et al. Cellular prostagiandin E-2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and-2 [ J ]. J Biol Chem, 2003, 278(39) : 37937-37947.
  • 8FORSBERG L, LEEB L, THOREN S, et al. Human glutathione dependent prostaglandin E synthase: gene structure and regulation [J]. FEBS Lett. 2000, 471 ( 1 ) : 78-82.
  • 9NARABA H, YOKOYAMA C. TAGO N, et al. Transcriptional regulation of the membrane-associated prostaglandin E-2 synthase gene-essential role of the transcription factor Egr-1[ J ]. J Biol Chem, 2002, 277(32): 28601-28608.
  • 10YUCEL-LINDBERG T, OLSSON T, KAWAKAMI T. Signal pathways involved in the regulation of prostaglandin E svnthase-1 in human gingivat fibroblasts[ J ]. Cell Signalling, 2006, 18 ( 12 ) : 2131-2142.

二级参考文献14

  • 1任亮,侯树坤,王晓峰,叶海云,管考鹏.塞来昔布对膀胱癌裸鼠皮下移植瘤及移植瘤细胞凋亡的影响[J].中华泌尿外科杂志,2006,27(S1):30-32. 被引量：3
  • 2张志宏,韩盛玺.RNA干扰Survivin基因治疗大肠癌作用机制的研究进展[J].世界华人消化杂志,2006,14(33):3215-3218. 被引量：4
  • 3HIDA T,YATABE Y, ACHIWA H,et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas[ J ]. Cancer Res, 1998,58 (17) : 3761- 3764.
  • 4BRABENDER J,PARK J, METZGER R,et al. Prognostic significance of cyclooxygenase-2 mRNA expression in non-small cell lung cancer[J]. Ann Surg,2002,235(6) : 896-897.
  • 5HASTURK S, KEMP B, KALAPURAKAL S K, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and non-small cell lung carcinoma [ J ]. Cancer, 2002,94 ( 4 ) : 1023-1031.
  • 6DUBINETT S M, SHARMA S, HUANG M, et al. Cyclooxygenase-2 in lung cancer [ J ]. Prog Exp Tumor Res, 2003,37 : 1384 162.
  • 7TANAKA T, DELONG PA, AMIN K, et al. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib potential value as adjuvant therapy after surgery [ J ]. Ann Surg,2005,241 ( 1 ), 168-178.
  • 8WICK M, HURTEAU G, DESSEV C, et al. Peroxisome proliferator-activated receptor gamma is a target of NSAID mediating cyelooxygenase independent inhibition of lung cancer cell growth [ J]. Mol Pharmacol, 2002,62 (5) : 1207-1214.
  • 9MASFERRER JL, LEAHY KM, KOKI AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors[ J]. Cancer Res ,2000,60(5) : 1306-1311.
  • 10KRYSAN K, MERCHANT F H, ZHU L,et al. COX-2-dependent stabilization of survivin in non-small cell lung cancer[ J]. FASEB J,2004,18 ( 1 ) : 206-208.

共引文献7

同被引文献16

  • 1杨光锐,管又飞.前列腺素E_2合酶的研究进展[J].生理科学进展,2006,37(2):182-186. 被引量：9
  • 2李曙光,张昕,李明,扈东艳.子宫内膜癌组织中环氧化酶-2与雌、孕激素受体的表达及相关性研究[J].现代妇产科进展,2007,16(2):121-123. 被引量：3
  • 3Gonzalez F, Rote NS, Minium J, et al. Evidence of proatherogenic inflammation in polycystic ovary syn- drome [ J ]. Metabolism, 2009,58 : 954 -962.
  • 4Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [ J ]. Fertil Steril, 2004,81 : 19-25.
  • 5Daniilidis A, Dinas K. Long term health consequences of polycystic ovarian syndrome : a review analysis [ J ]. Hippokratia,2009,13:90-92.
  • 6Dhindsa G, Bhatia R, Dhindsa M, et al. Insulin resistance, insulin sensitization and inflammation in polycystic ovari- an syndrome[ J]. J Postgrad Med ,2004 ,50 : 140-144.
  • 7Laure D, Sabina R, Susen B, et al. Obesity, inflammatory markers,and endometrial cancer risk:a prospective case- control study [ J ]. Endocrine-Related Cancer, 2010, 17 : 1007-1019.
  • 8Diamanti-Kandarakis E, Christakou CD, Kandaraki E, et al. Metformin : an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome [ J ]. Eur J Endocrinol, 2010, 162:193-212.
  • 9乔杰.多囊卵巢综合症[M].北京:北京大学医学出版社,2010:120.
  • 10侯灵彤,郑桓,高鹰.青春期PCOS患者血清C反应蛋白水平的变化及意义[J].山东医药,2008,48(12):4-6. 被引量：1

引证文献2

二级引证文献3

肿瘤
2009年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部